动物造模 z-bio 2023-01-16 713

　　Objective: To evaluate the safety of hBMSCs transplanted into the brain of juvenile cynomolgus monkeys, and to further observe the migration and distribution of hBMSCs in the brain, so as to establish a new technical platform and theoretical basis for the treatment of children's central nervous system diseases.

　　Methods: Direct injection of hBMSCs into the brain of juvenile cynomolgus monkeys, and observe the inflammatory response and immune rejection at the injection site by HE staining and immunohistochemistry methods; observe by using hBMSCs in vitro labeling and tracing and detection of male-specific genes carried The migration and distribution of hBMSCs in the brain after transplantation.

　　Results: The results of the study showed that direct intracerebral injection of hBMSCs did not cause systemic symptoms in the test animals, the inflammatory response of the brain tissue at the transplantation site was limited, no obvious immune rejection, no brain tissue degeneration and necrosis, and no obvious glial cell proliferation and aggregation. After 4 weeks of transplantation, hBMSCs are still alive in large numbers and can migrate widely in the brain. Their migration distribution has a certain regularity, and the overlap of cell distribution in different transplant recipients can be observed. In addition, the migration and distribution of hBMSCs has a tendency to migrate from the forebrain to the back of the brain and to the blood vessels and subependymal.

　　Conclusion: hBMSCs directly injected and transplanted into the brain is safe; hBMSCs can survive and migrate in the brain for a long time.